Jeffrey Smith is a Dermatology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Galderma Laboratories, L.P.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
32.9%Interleukin-4 Receptor alpha Antagonist28%Dupixent Pen84%Dupixent Syringe16%Part D<11 patientsCorticosteroid4.9%Triamcinolone Acetonide100%Part D<11 patientsCancer & immunology
25.1%Folate Analog Metabolic Inhibitor15.2%Methotrexate100%Part D<11 patientsJAK inhibitor4.9%Rinvoq100%Part D<11 patients+ 1 more class in this area
Antiparasitic
15.6%Antimalarial15.6%Hydroxychloroquine Sulfate71%Chloroquine Phosphate29%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Biochemical Determinants of Chemokine Receptor Signaling
Brigham and Women'S Hospital
FY2026$170,264K08AR084617 - Biochemical Determinants of Chemokine Receptor Signaling
Brigham and Women'S Hospital
FY2025$168,029K08AR084617 - Biochemical Determinants of Chemokine Receptor Signaling
Brigham and Women'S Hospital
FY2024$163,514K08AR084617
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Joel Gelfand, MD
University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”